Olanzapine tablets coated

国家: 亚美尼亚

语言: 英文

来源: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

下载 产品特点 (SPC)
19-04-2018

有效成分:

olanzapine

可用日期:

Arpimed LLC

ATC代码:

N05AH03

INN(国际名称):

olanzapine

剂量:

5mg

药物剂型:

tablets coated

每包单位数:

(24/1x24/) in blister

处方类型:

Prescription

授权状态:

Registered

授权日期:

2018-04-18

产品特点

                                SUMMARY PRODUCT CHARACTERISTIC (SPC)
OLANZAPINE
5 MG AND 10 MG COATED TABLETS
1.1 BRAND NAME – OLANZAPINE
1.2 INTERNATIONAL NON-PROPERTY NAME - OLANZAPINE
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each Olanzapine 5 mg coated tablet contains:
_ACTIVE INGREDIENT:_ olanzapine_ _ - 5 mg
_For a full list of excipients, see section 6.1. _
Each Olanzapine 10 mg coated tablet contains:
_ACTIVE INGREDIENT:_ olanzapine_ _ - 10 mg
_For a full list of excipients, see section 6.1. _
3. PHARMACEUTICAL FORM
_Olanzapine, 5 mg coated tablets _
White or white off biconvex film-coated tablets.
_Olanzapine, 10 mg coated tablets _
White or white off biconvex film-coated tablets.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
_Adults_
Olanzapine is indicated for the treatment of schizophrenia.
Olanzapine is effective in maintaining the clinical improvement during
continuation therapy in
patients who have shown an initial treatment response.
Olanzapine is indicated for the treatment of moderate to severe manic
episode.
In patients whose manic episode has responded to olanzapine treatment,
olanzapine is indicated for
the prevention of recurrence in patients with bipolar disorder (see
section 5.1).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Adults
Schizophrenia: The recommended starting dose for olanzapine is 10
mg/day.
Manic episode: The starting dose is 15 mg as a single daily dose in
monotherapy or 10 mg daily in
combination therapy (see section 5.1).
Preventing recurrence in bipolar disorder: The recommended starting
dose is 10 mg/day. For
patients who have been receiving olanzapine for treatment of manic
episode, continue therapy for
preventing recurrence at the same dose. If a new manic, mixed, or
depressive episode occurs,
olanzapine treatment should be continued (with dose optimisation as
needed), with supplementary
therapy to treat mood symptoms, as clinically indicated.
During treatment for schizophrenia, manic episode, and recurrence
prevention in bipolar disorder,
daily dosage may subsequently be adjusted on the basis
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 俄文 19-04-2018

搜索与此产品相关的警报